Primary Outcome Measures Disease-related Symptom Burden 3 Months After Partial Pleurectomy (Surgery) Secondary Outcome Measures Quality of Life of Study Participants Who Have Undergone Partial Pleurectomy (Surgery) Rate of Complications after Partial Pleurectomy (Surgery) Time to Resumption of Systemic Therapy Overall Survival of Study Participants Who Have Undergone Partial Pleurectomy[…]
Not Yet Recruiting
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
Primary Outcome Measures ORR Inclusion Criteria Subjects must provide informed consent prior to initiating any study-specific procedures. Male or female subjects aged ≥18 and ≤75 years. Histologically/cytologically confirmed malignant mesothelioma (MM), including malignant pleural mesothelioma (PM) and malignant peritoneal mesothelioma (PeM). Subjects with MM unsuitable for radical resection and/or radiotherapy[…]
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Primary Outcome Measures Establish the recommended phase 2 dose (RP2D) of TNhYP218 CAR T cells based on dose-limiting toxicity (DLT) of defined adverse events (AEs). Determine the preliminary objective response rate of TNhYP218 CAR T cells in a limited number of participants with mesothelioma treated at the recommended phase 2[…]
Evaluating Ivonescimab As a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy (Bi-MAPS)
Primary Outcome Measures The analysis of the primary efficacy endpoint will be conducted in all eligible patients, based on the disease control rate (DCR) at 12 weeks according to mRECIST 1.1 for mesothelioma, which was defined as the proportion of patients with compete response (CR), partial response (PR) or stable[…]
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).
A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001)
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Primary Outcome Measures Number of participants treated with Alintegimod monotherapy with treatment related adverse events as assessed by CTCAEv5.0 Number of participants treated with Alintegimod in combination with treatment related adverse events as assessed by CTCAEv5.0 Define RPTDs for Alintegimod Secondary Outcome Measures Characterize Pharmacokinetics of Alintegimod monotherapy by measuring[…]
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma (PENINSULA)
In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma.
